Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN Partners with Exosome Diagnostics

Published: Wednesday, July 24, 2013
Last Updated: Wednesday, July 24, 2013
Bookmark and Share
Molecular testing of biofluids promises unprecedented access to gene mutations, gene expression signatures and expression levels without costly, invasive tissue biopsies.

QIAGEN N.V. announced a partnership with Exosome Diagnostics Inc. to develop and commercialize high-performance sample preparation kits for the processing of nucleic acids from exosomes. Combining the Exosome Diagnostics platform technology approach with select QIAGEN consumables and automation platforms has the potential to allow researchers, drug developers and doctors to take repeated, real-time genetic "snapshots" of disease from patients’ blood, urine or cerebrospinal fluid without the need for tissue biopsy. The companies are targeting initial product launches in the first half of 2014. Financial terms were not disclosed.

Subject to successful performances of these new solutions, QIAGEN’s exclusive agreement with Exosome Diagnostics will cover co-development, manufacturing and commercialization of a full product line for the life science and translational medicine markets.  First applications of Exosome Diagnostics’ technology are being developed with QIAGEN’s microRNA isolation solutions and are designed to run on QIAGEN automated instrument platforms. The product portfolio is also expected to create the basis for development and commercialization of clinical in-vitro diagnostic products for a range of non-invasive personalized healthcare solutions.

Exosomes are one of many different subpopulations of microvesicles that can be isolated from biofluids such as blood, urine and cerebrospinal fluid and from which high-quality RNA and DNA can be extracted and purified for analysis. Exosomes are shed by cells under both normal and pathological conditions. They are a key part of the body’s complex communication system that transfers genetic instructions from cell to cell through all biofluids. Exosomes carry nucleic acids and proteins from their host cells and are widely considered to be essential for biomarker discovery for personalized healthcare diagnostics. Tumor cells, for instance, release exosomes which contain tumor-specific RNAs that can be isolated easier from biofluids such as blood and urine than from biopsies. Exosome Diagnostics’ proprietary technology makes use of the presence and stability of nucleic acids in exosomes to detect and measure levels of genes implicated in cancer, neurodegenerative, metabolic, infectious and other diseases.

“QIAGEN is a global leader in personalized healthcare solutions, and Exosome Diagnostics is a leading developer in biofluid-based molecular testing. Together we expect to create the ‘gold standard’ in this emerging field of exosome-based testing, advancing research and improving healthcare,” said Dirk Loeffert, Vice President Global Product Development Life Sciences of QIAGEN. “We believe QIAGEN can bring to market the first comprehensive line of products to help researchers and pharmaceutical companies explore and monitor disease status using fresh or frozen biofluids, addressing the critical challenge of access to samples. We also intend to co-develop exosome-based workflows for routine use in personalized healthcare, a revolutionary improvement compared to today’s widespread dependence on tissue biopsies, offering the ability to create a new dimension of utility for our molecular testing assay portfolio. This approach holds promise to significantly improve medical care as physicians may be able to use real-time molecular information to change the care pathway and bring about disease management.”

James McCullough, Chief Executive Officer of Exosome Diagnostics, said: “Our partnership with QIAGEN brings unprecedented access to key genetic information directly from a patient’s biofluid sample for academic, biomedical research and pharmaceutical drug programs around the world. We expect this partnership, focused on development of a broad range of products, will help accelerate commercialization of the next generation of minimally invasive, clinical-grade diagnostics for personalized healthcare.”

QIAGEN’s exosome technology-driven kits will offer distinct advantages including the ability to work with scalable patient sample volumes, from as little as 200µL; RNA capture from frozen, bio-banked fluids; the use of plasma, urine and cerebrospinal fluid with no special stabilization or handling required; and streamlined clinical laboratory workflow for analysis on PCR, pyrosequencing and next-generation sequencing (NGS) instruments. Previously, such analysis would have depended on the use of tissue and/or cells, potentially requiring invasive procedures for patients.

As part of an active biological packaging and distribution mechanism for RNA and DNA, exosomes and their nucleic acid contents are being investigated for their implications and utility in a broad range of diseases including cancer, central nervous system disorders such as Alzheimer’s and Parkinson’s diseases, cardiovascular disease, maternal/fetal medicine, and chronic kidney disease. The natural stability of the exosome compartment allows collection of clinical samples without special tubes or preservatives. As a result, researchers can perform analysis and biomarker discovery on high-quality RNA from both fresh and frozen plasma, serum, urine and cerebrospinal fluid samples. This is of particular interest for analysis of RNA-based biomarkers such as ALK or RET.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Qiagen Bids $100M to Acquire Exiqon
Transaction will expand leadership position in RNA technologies.
Thursday, March 31, 2016
Qiagen and 10x Genomics to Enter Into Co-Marketing and Co-Development Collaboration
Company has announced that the multi-phase collaboration to advance next-generation sequencing, single-cell biology, and bioinformatics Sample to Insight solutions.
Wednesday, February 17, 2016
QIAGEN Collaborates with Allele Frequency Community
QIAGEN providing secure bioinformatics infrastructure and software for research and clinical labs to contribute and gain insights from Allele Frequency Community.
Wednesday, February 25, 2015
QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics
Master collaboration agreement is a framework for developing and commercializing QIAGEN companion diagnostics, paired with new or existing products.
Thursday, November 13, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
QIAGEN Reports Fourth Quarter and Full-Year 2013 Results
Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.
Thursday, January 30, 2014
QIAGEN Acquires CLC Bio
This acquisition enables QIAGEN to create a complete workflow from biological sample to valuable molecular insights.
Wednesday, October 30, 2013
QIAGEN Acquires Ingenuity Systems
Suite of web-based applications powered by a unique expert-curated Knowledge Base eases major bottlenecks to leveraging genomic data in research and clinical diagnostics.
Thursday, May 02, 2013
QIAGEN Unveils Initiative to Create Next-generation Sequencing Portfolio
Company plans to offer sample-to-result workflows that integrate its sample preparation and assay products with a next-generation benchtop sequencer and new bioinformatics.
Tuesday, June 26, 2012
Scientific News
How Did The Giraffe Get Its Long Neck?
Clues about the evolution of the giraffe’s long neck have now been revealed by new genome sequencing.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Making Genetic Data Easier to Search
Scripps team streamlines biomedical research by making genetic data easier to search.
Collaborative Study of WES Offers New Hope
Company has announced that the collaborative study of whole exome sequencing offers new hope for children with white matter disorders.
Using Portable Nanopore DNA Sequencers to Combat Wildlife Crime
University of Leicester researchers aim to develop a test using DNA to identify species at crime scenes in as little as an hour.
TGAC Installs Largest SGI UV 300 Supercomputer for Life Sciences
The Genome Analysis Centre (TGAC) partners with Global HPC hardware giant SGI to address the most complex problems in genomics analysis.
Shining A Light On Bladder Cancer
Researchers scrutinize patterns of mutations in bladder tumor genomes, gleaning insights into the roles of DNA repair and tobacco-related DNA damage.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
Five New Breast Cancer Genes Found
Discovery of mutations paves the way for personalised treatment of breast cancer.
New Neurodevelopmental Syndrome Identified
Study pinpoints underlying genetic mutations, raising hopes for targeted therapies.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!